Jeffrey Walch
Stock Analyst at Bernstein
(2.64)
# 2,921
Out of 4,988 analysts
22
Total ratings
70%
Success rate
7.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $376 | $239.56 | +56.95% | 2 | Sep 16, 2026 | |
| SMMT Summit Therapeutics | Upgraded: Hold | $9.8 → $12 | $17.85 | -33.33% | 5 | Aug 25, 2026 | |
| RVMD Revolution Medicines | Reiterated: Hold | $151 → $179 | $190.95 | -6.26% | 4 | Aug 20, 2026 | |
| INCY Incyte | Reiterated: Hold | $99 → $104 | $125.31 | -17.01% | 2 | Aug 12, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $221 → $218 | $146.23 | +49.08% | 3 | Aug 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $608 | $508.34 | +19.60% | 1 | Aug 11, 2026 | |
| BNTX BioNTech SE | Reiterated: Hold | $96 | $96.06 | -0.06% | 3 | Aug 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $240.74 | -4.88% | 2 | Jun 8, 2026 |
Alnylam Pharmaceuticals
Sep 16, 2026
Reiterated: Buy
Price Target: $376
Current: $239.56
Upside: +56.95%
Summit Therapeutics
Aug 25, 2026
Upgraded: Hold
Price Target: $9.8 → $12
Current: $17.85
Upside: -33.33%
Revolution Medicines
Aug 20, 2026
Reiterated: Hold
Price Target: $151 → $179
Current: $190.95
Upside: -6.26%
Incyte
Aug 12, 2026
Reiterated: Hold
Price Target: $99 → $104
Current: $125.31
Upside: -17.01%
Neurocrine Biosciences
Aug 12, 2026
Reiterated: Buy
Price Target: $221 → $218
Current: $146.23
Upside: +49.08%
Vertex Pharmaceuticals
Aug 11, 2026
Reiterated: Buy
Price Target: $608
Current: $508.34
Upside: +19.60%
BioNTech SE
Aug 4, 2026
Reiterated: Hold
Price Target: $96
Current: $96.06
Upside: -0.06%
Jazz Pharmaceuticals
Jun 8, 2026
Reiterated: Hold
Price Target: $229
Current: $240.74
Upside: -4.88%